Dr. Shadman on Fixed Durations of Treatment in... - CLL Support

CLL Support

23,324 members40,026 posts

Dr. Shadman on Fixed Durations of Treatment in CLL

Jm954 profile image
Jm954Administrator
6 Replies

Mazyar Shadman, MD, MPH

Published: Monday, Jul 08, 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington School of Medicine, and attending physician, Seattle Cancer Care Alliance, discusses fixed durations of treatment in chronic lymphocytic leukemia (CLL).

"Last year, many patients would likely opt for a chemoimmunotherapy regimen as opposed to an oral drug like ibrutinib (Imbruvica) because it is a fixed duration of treatment, says Shadman. After approximately 6 months, patients could enjoy their remission off treatment, which could last for years.

Now, patients have the added option of considering a nonchemotherapy drug that gives them the opportunity of potentially having a fixed duration of treatment. However, this is not a guarantee because studies, such as CLL14 or MURANO, were designed to give venetoclax (Venclexta) in combination with a CD20-targeted antibody for 1 and 2 years, respectively. It is not yet known what happens after these patients stop treatment. In the phase III MURANO study, there are short-term data to suggest that patients who achieve a deep remission may be relapse-free for a long time."

See the video and more here: onclive.com/onclive-tv/dr-s...

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
Read more about...
6 Replies
t2aa profile image
t2aa

This is my doc that I see on Monday to start Venetoclax!

Jm954 profile image
Jm954Administrator in reply tot2aa

WooooHoooo, lucky you !!!! Good luck for Monday :)

Beattiem-UK profile image
Beattiem-UK

Thankyou Jackie. We live in hope...

Beattie

rafew profile image
rafew

This is the decision I'm facing now for treatment. Ibrutinib or Venetoclax plus Rituxan. Waiting for complete labs before making the decision. Thanks for the post.

Jm954 profile image
Jm954Administrator in reply torafew

It's a difficult decision but good to have the choice.

You have no choice but to make a decision, it could be many years before we know which is best for which patients. At the moment, both look good.

Jackie

Dr Shadman is the Dr who said I had 5-7 years before I would need treatment. That was January 2018. I started treatment 10 months later, November 2018. I believe that’s due to me being 11q deleted & unmutated.

There is still so much unknown. I chose BR because I wanted a fixed duration of treatment. There’s still too much unknown for the non chemo drugs. I’m 38 and will need treatment again at some point. I was told remission could be as short as 6 months but might be several years. I am hoping that they will know more by the time I need treatment again.

Not what you're looking for?

You may also like...

CLL Research: Phase 2 CAPTIVATE Study Suggests Role for Fixed-Duration Treatment of CLL/SLL

https://cllpharmacist.com/cll-research-phase-2-captivate-study-suggests-role-for-fixed-duration-trea
WinJ3 profile image

Expert Reviews Current State of CLL Treatment, Dr. Brander, Duke U

Recent developments in the treatment of patients with chronic lymphocytic leukemia (CLL) have...
Cllcanada profile image
Top Poster CURE Hero

Video interviews; CLL 'Hot Topics and Maturing Data' ASH 2019: Prof John Gribben, Prof Pete Hillmen, Dr George Follows & Dr Renata Walewska

In December, the Leukaemia Care Patient Advocacy team attended the annual American Society of...
HAIRBEAR_UK profile image
Founder Admin

Outcomes after UMRD with 1st line Ib +Ven Fixed Duration Treatment Versus Continued Ibr Follow-up in the CAPTIVATE Study

First-line Ibr + Ven is an all-oral, once-daily, chemotherapy-free regimen that continues to...
Jm954 profile image
Administrator

Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...
lankisterguy profile image
Volunteer